Alex Gorsky, J&J CEO (Evan Vucci/AP Images)

Covid-19 roundup: J&J en­ters PhI­II with a two-dose reg­i­men to play safe; As­traZeneca, Ox­ford tout promis­ing da­ta in el­der­ly

John­son & John­son had the first sin­gle-dose Covid-19 vac­cine to en­ter Phase III tri­als — but to be cau­tious, the phar­ma is launch­ing a sec­ond Phase III study eval­u­at­ing the can­di­date in a two-dose reg­i­men.

“Janssen’s COVID-19 vac­cine pro­gram has been de­signed to be ex­treme­ly thor­ough and dri­ven by sci­ence,” the com­pa­ny an­nounced on Sun­day. “As such, we are in­ves­ti­gat­ing mul­ti­ple dos­es and dos­ing reg­i­mens to eval­u­ate their long-term ef­fi­ca­cy.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.